GPCR Stock Forecast & Price Target

Structure Therapeutics is supported by a differentiated oral GPCR platform and a lead asset, aleniglipron, that has shown durable efficacy through 72 weeks with up to 16.2% weight loss, no plateau at higher doses, and favorable liver safety, while a lower 2.5 mg starting dose meaningfully improved tolerability and cut discontinuations. The company also benefits from a large Phase 3 ACCOMPLISH program now underway, including up to 3,600 obesity or overweight patients with comorbidities and 1,100 with T2D, which should generate decisive validation of both weight-loss and glycemic-control potential in 2H28. Additional upside comes from the emerging oral amylin franchise, where ACCG-2671 has already shown target engagement, dose-proportional PK, and up to 3.3% weight loss after a single dose, supporting a pipeline with multiple near-term catalysts and more than $8B estimated peak sales potential.

Structure Therapeutics is facing a negative fundamental setup because aleniglipron still must clear larger Phase 3 trials after promising Phase 2b data, and those later results may not replicate earlier efficacy or tolerability. Competitive pressure is intensifying, with several approved GLP-1 therapies and more than 20 programs in development, so the company needs a highly differentiated profile to win share against entrenched big pharma-backed drugs and may require a commercial partner. Financially, it is expected to continue incurring net losses at least until commercialization and likely through the early launch phase, while additional capital needs could dilute shareholder value, justifying a lower penetration outlook.